2.3
2022

Economic burden of severe asthma in Turkey: a cost of illness study from payer perspective

Show more: Authors information and Publication history
Authors Information

1Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey
2Department of Health Care Management, Faculty of Medical Sciences, Baskent University, Ankara, Turkey
3Department of Chest Diseases, School of Medicine, Ege University, Izmir, Turkey
4Department of Pulmonary Diseases, Cerrahpaºa Faculty of Medicine, Istanbul University-Cerrahpaºa, Istanbul, Turkey
5School of Medicine, Gazi University, Ankara, Turkey
6Department of Family Medicine, School of Medicine, Baskent University, Ankara, Turkey
7Department of Chest Diseases, School of Medicine, Dr. Suat Günsel University of Kyrenia Hospital, Kyrenia, Cyprus
8Department of Chest Diseases, School of Medicine, Celal Bayar University, Manisa, Turkey

History

Published online: 30 April 2020
Accepted: 21 April 2020
Received: 12 January 2020

SUMMARY

Objective. To estimate economic burden of severe asthma in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods. This cost of illness study was based on identification of per patient annual direct medical costs for the management of sever easthma in Turkey from payer perspective. Average per patient direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations and interventions, drug treatment and equipment, and co-morbidities/complications. Results. Based on total annual per patient costs calculated for outpatient admission ($ 177.91), laboratory and radiological tests ($ 82.32), hospitalizations/interventions ($ 1,154.55), drug treatment/equipment ($ 2,289.63) and co-morbidities ($ 665.39) cost items, total per patient annual direct medical costrelated to management of severe asthma was calculated to be $ 4,369.76 from payer perspective. Drug treatment/equipment (52.4%) was the main cost driver in the management of severe asthma in Turkey, as followed by hospitalizations/interventions (26.4%) and co-morbidities (15.2%). Conclusions. In conclusion, our findings indicate that managing patients with severe asthma pose a considerable burden to health economics in Turkey, with medications as the main cost driver.

KEY WORDS
Severe asthma; asthma attack; practice patterns; direct costs; cost analysis; Turkey.

Table of Content: Vol. 53 (No. 3) 2021 May

European Annals of Allergy and Clinical Immunology ISSN 1764-1489 | © 2024